

Please amend claims 1 and 3 to read as follows:

1. A dry, storage stable, sterile dressing for application to a bleeding site which comprises a dry hemostatic zone, said zone comprising a matrix containing hemostatis-promoting amount of a hemostatic agent which accelerates blood coagulation and clot formation at an interface between the bleeding site and the hemostatic zone wherein said hemostatic agent comprises beads of cross-linked dextran wherein said cross-linked dextran triggers release of clotting factors and other ancillary substances which initiate a physiological clotting process when applied to the bleeding site.

3. The dry, sterile, dressing according to claim 1 wherein the dressing is affixed to a substrate. *Yes/No?*

33,54 REMARKS
Claims 1, 3, 9, 11 to 13 and 41 are pending before the Examiner for consideration on the merits. Claims 14 to 24, 26, 28 to 37, 40 to 42 and 45 to 63 which were withdrawn from consideration by the Examiner as being drawn to non-elected inventions. These claims have been cancelled in compliance with the Examiner's requirement. Applicants reserve the right to file a divisional application to this subject matter with all the rights afforded by 35 U.S.C. § 121.

The Examiner has required corrections to page 21, second and third paragraphs. These inadvertent misspellings have been corrected. With respect to the Examiner's comment relating to the hemostatic copolymer and the essence of the novelty of the present invention, applicants present the following observation. Cross-linked dextrans are not themselves the essence of the present invention but rather it is the fact that particular cross-linked dextrans have specific novel utility. Applicants have found that, if particular cross-linked dextran beads are applied to a bleeding site, the beads trigger release of clotting factors and other ancillary factors so as to induce a physiological clotting process at the bleeding site.